PD 04 - AFFiRisAlternative Names: a-Syn PD 04; Affitope PD 04; PD04
Latest Information Update: 13 Sep 2016
At a glance
- Originator AFFiRiS
- Class Peptide vaccines
- Mechanism of Action Alpha-synuclein inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Parkinson's disease
Most Recent Events
- 08 Sep 2016 Preclinical trials in Parkinson's disease in Austria (Parenteral) before September 2016 (AFFiRis pipeline, September 2016)